Peg Biosciences
PEG Biosciences Inc (PBI) is a biotechnology company based in New Jersey, USA, dedicated to developing innovative therapeutics targeting unmet medical needs. The company specializes in proprietary drug delivery technologies, BioSynersys™ and ProbioTherapeutic™, to create first-in-class and best-in-class drugs, particularly in cancer, infectious, and autoimmune diseases. PBI collaborates with pharmaceutical and biotech partners to develop and commercialize advanced biologics and therapeutics, aiming to harness the full potential of biologics for treating life-threatening diseases.
Industries
Nr. of Employees
small (1-50)
Peg Biosciences
195 Blackhorse Lane, North Brunswick Township, NJ 08902
Products
Protein–polymer conjugation platform (site-specific conjugation)
Platform technology for creating synergy-enhanced PEG conjugates of proteins and peptides to improve activity, stability, solubility and half-life of biologics.
PB307 (immuno-oncology candidate)
Preclinical immuno-oncology biologic shown in animal models to increase tumor infiltrating lymphocytes and modulate the tumor microenvironment to enhance antitumor immune responses.
PB121 (cytokine formulation)
Improved cytokine formulation designed to activate NK and T effector cells and to counteract immunosuppressive tumor microenvironment components.
PB718 (addiction and pain therapeutic)
Biologic formulation developed for treatment of drug addiction and for reducing opioid withdrawal symptoms and central opiate effects.
PB922 (anti-inflammatory / autoimmune candidate)
Biologic formulation aimed at regulating cytokine production and T cell proliferation for treatment of autoimmune diseases such as multiple sclerosis, Crohn’s disease, ulcerative colitis and rheumatoid arthritis.
PB844 (neurologic / neurodegenerative candidate)
Formulated naturally occurring biologic under development for treatment of neurologic disorders and neurodegenerative diseases.
Protein–polymer conjugation platform (site-specific conjugation)
Platform technology for creating synergy-enhanced PEG conjugates of proteins and peptides to improve activity, stability, solubility and half-life of biologics.
PB307 (immuno-oncology candidate)
Preclinical immuno-oncology biologic shown in animal models to increase tumor infiltrating lymphocytes and modulate the tumor microenvironment to enhance antitumor immune responses.
PB121 (cytokine formulation)
Improved cytokine formulation designed to activate NK and T effector cells and to counteract immunosuppressive tumor microenvironment components.
PB718 (addiction and pain therapeutic)
Biologic formulation developed for treatment of drug addiction and for reducing opioid withdrawal symptoms and central opiate effects.
PB922 (anti-inflammatory / autoimmune candidate)
Biologic formulation aimed at regulating cytokine production and T cell proliferation for treatment of autoimmune diseases such as multiple sclerosis, Crohn’s disease, ulcerative colitis and rheumatoid arthritis.
PB844 (neurologic / neurodegenerative candidate)
Formulated naturally occurring biologic under development for treatment of neurologic disorders and neurodegenerative diseases.
Services
Licensing and collaborative partnerships to apply protein conjugation and drug-delivery platform technologies to external biologics and peptides.
Collaborative programs with academic and translational research centers for preclinical evaluation of immuno-oncology, neuroscience and antiviral candidates.
Formulation and manufacture of a botanical nasal sanitizer product intended for topical use in the upper airways; distributed as a finished consumer health product.
Licensing and collaborative partnerships to apply protein conjugation and drug-delivery platform technologies to external biologics and peptides.
Collaborative programs with academic and translational research centers for preclinical evaluation of immuno-oncology, neuroscience and antiviral candidates.
Formulation and manufacture of a botanical nasal sanitizer product intended for topical use in the upper airways; distributed as a finished consumer health product.
Expertise Areas
- Biologic drug delivery and PEGylation
- Protein conjugation platform development
- Immuno-oncology therapeutic development
- Preclinical pharmacology and toxicology
Key Technologies
- PEG-based protein conjugation
- Site-specific conjugation chemistry
- Protein–polymer conjugation
- Cytokine formulation